Abstract:ABSTRACT Individuals with latent tuberculosis infection (LTBI) account for almost 30% of the population worldwide and have the potential to develop active tuberculosis (ATB). Despite this, the current understanding of the pathogenesis of LTBI is limited. The gut microbiome can be altered in tuberculosis patients, and an understanding of the changes associated with the progression from good health to LTBI to ATB can provide novel perspectives for understanding the pathogenesis of LTBI by identifying microbial and molecular biomarkers associated therewith. In this study, fecal samples from healthy controls (HC), individuals with LTBI and ATB patients were collected for gut microbiome and metabolomics analyses. Compared to HC and LTBI subjects, participants with ATB showed a significant decrease in gut bacterial α-diversity. Additionally, there were significant differences in gut microbial communities and metabolism among the HC, LTBI, and ATB groups. PICRUSt2 analysis revealed that microbiota metabolic pathways involving the degradation of purine and pyrimidine metabolites were upregulated in LTBI and ATB individuals relative to HCs. Metabolomic profiling similarly revealed that purine and pyrimidine metabolite levels were decreased in LTBI and ATB samples relative to those from HCs. Further correlation analyses revealed that the levels of purine and pyrimidine metabolites were negatively correlated with those of gut microbial genera represented by Ruminococcus_gnavus_group ( R. gnavus ), and the levels of R. gnavus were also positively correlated with adenosine nucleotide degradation II, which is a purine degradation pathway. Moreover, a combined signature including hypoxanthine and xanthine was found to effectively distinguish between LTBI and HC samples (area under the curve [AUC] of training set = 0.796; AUC of testing set = 0.924). Therefore, through gut microbiome and metabolomic analyses, these findings provide valuable clues regarding how alterations in gut purine and pyrimidine metabolism are linked to the pathogenesis of LTBI. IMPORTANCE This study provides valuable insight into alterations in the gut microbiome and metabolomic profiles in a cohort of adults with LTBI and ATB. Perturbed gut purine and pyrimidine metabolism in LTBI was associated with the compositional alterations of gut microbiota, which may be an impetus for developing novel diagnostic strategies and interventions targeting LTBI.

Altered Intestinal Microbiota and Fecal Metabolites in Patients with Latent and Active Pulmonary Tuberculosis

Characteristic gut microbiota and metabolic changes in patients with pulmonary tuberculosis

Alterations in the Gut Microbiome of Individuals With Tuberculosis of Different Disease States

A metagenomic study of the gut microbiome in PTB’S disease

Alterations of gut microbiota in patients with active pulmonary tuberculosis in China: a pilot study

Alterations in purine and pyrimidine metabolism associated with latent tuberculosis infection: insights from gut microbiome and metabolomics analyses

The Microbiota of Human Lung of Pulmonary Tuberculosis and the Alteration Caused by Anti-tuberculosis Drugs.

Alternation of Gut Microbiota in Patients with Pulmonary Tuberculosis

Characterization of Gut Microbiota in Children with Pulmonary Tuberculosis.

The Gut Microbiome Signatures Discriminate Healthy from Pulmonary Tuberculosis Patients

Distinct Lung Microbial Community States in Patients with Pulmonary Tuberculosis

The Characteristics of the Gut Microbiota in Patients with Pulmonary Tuberculosis: A Systematic Review

Clostridium, Bacteroides and Prevotella Associates with Increased Fecal Metabolites Trans-4-Hydroxy-L-proline and Genistein in Active Pulmonary Tuberculosis Patients During Anti-Tuberculosis Chemotherapy with Isoniazid-Rifampin-pyrazinamide-ethambutol (HRZE)

The Potential Mechanism of the Progression from Latent to Active Tuberculosis Based on the Intestinal Microbiota Alterations.

Metagenomic Analysis of the Lung Microbiome in Pulmonary Tuberculosis-a Pilot Study

Dynamic changes of respiratory microbiota associated with treatment outcome in drug-sensitive and drug-resistant pulmonary tuberculosis

Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosis

Gut microbiota associated with pulmonary tuberculosis and dysbiosis caused by anti-tuberculosis drugs.

The impact of anti-tuberculosis treatment on respiratory tract microbiome in pulmonary tuberculosis

Microbiota alterations in patients treated for susceptible or drug-resistant TB

[A Comparative Study on the Difference of Gut Microbiota and Its Biomarkers Between Patients with Pulmonary Tuberculosis and Healthy Controls].